Remote Ischemic Preconditioning in Carotid PCI: Safe and Effective?

Remote Ischemic Preconditioning in Carotid PCIRemote ischemic preconditioning (RIPC) can prevent recurrent ischemic events in patients with acute or chronic cerebral ischemia. However, is remains unclear whether RIPC could prevent an ischemic event in the context of carotid PCI in patients with severe carotid artery stenosis.

 

The study included patients with severe carotid artery stenosis randomized to RIPC, vs. two control groups, a sham RIPC group and a non- intervention group.

 

Patients in the RIPC arm received the procedure twice a day two weeks prior carotid artery stenting (CAS), as well as patients in the sham RIPC control group.

 

NSE and S-100B plasma levels were measured to assess RIPC safety; C reactive protein levels and new ischemic lesions were measure with MRI to assess efficacy.

 

Primary end point was the presence of new lesions measured by diffusion weight imaging within 48 hours after CAS, and clinical events within 6 months.

 

189 were randomized in all, (63 in each arm). Both RIPC and sham RIPC were well tolerated and completed with high compliance (98.41% and 95.24% respectively). There were no significant changes of NSE or S-100B, or adverse events.

 

The incidence of new diffusion weight imaging lesions was significantly lower than in the RIPC group (15.87%) compared to the sham RIPC group (36.51%, p<0.01) or the control group (41.27%, p<0.01). Lesion volume also resulted significantly lower (p<0.01).

 

As regards post CAS clinical events, there were 1 transient ischemic attack in the RIPC group, 2 strokes in the control group, and 2 strokes and 1 transient ischemic attack in the sham RIPC group, with no statistical importance.

 

Conclusion

RIPC is safe before CAS and it could also reduce periprocedural events risk. However, RIPC mechanisms and effects on clinical events still call for further research.

 

Original Title: Safety and Efficacy of Remote Ischemic Preconditioning in Patients with Severe Carotid Artery Stenosis Prior to Carotid Artery Stenting: A Proof-of-Concept, Randomized Controlled Trial.

Reference: Wenbo Zhao et al. Circulation. 2017 Feb 7. [Epub ahead of print].


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...

IVUS-Guided vs. Angiography-Guided Drug-Coated Balloon Angioplasty in the Treatment of Femoropopliteal Lesions

Angiography has traditionally been the primary imaging technique for endovascular therapy guidance in patients with peripheral artery disease. However, as it only provides two-dimensional...

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...